Research Topics
Species | HAROLD DVORAKSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Discovery of vascular permeability factor (VPF)Harold F Dvorak
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA
Exp Cell Res 312:522-6. 2006
Vascular permeability, vascular hyperpermeability and angiogenesisJanice A Nagy
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Angiogenesis 11:109-19. 2008..Further work will be required to elucidate the signaling pathways by which each of these molecules, and others likely to be discovered, mediate the different types of vascular permeability...- Tumor microenvironment and progressionHarold F Dvorak
Department of Pathology, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
J Surg Oncol 103:468-74. 2011..Also, breast cancers arise as the result of epigenetic as well as genetic changes. Tumor blood vessel pericytes result, in part, from bone marrow precursor cells, and VEGF is a negative regulator of glioblastoma tumor cell invasion... - Vascular permeability to plasma, plasma proteins, and cells: an updateHarold F Dvorak
Center for Vascular Biology Research and the Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Curr Opin Hematol 17:225-9. 2010..The mechanisms responsible for these events have been the subject of intense investigation and, often, dispute... - Rous-Whipple Award Lecture. How tumors make bad blood vessels and stromaHarold F Dvorak
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
Am J Pathol 162:1747-57. 2003 - Angiogenesis: update 2005H F Dvorak
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
J Thromb Haemost 3:1835-42. 2005..Finally, it will touch on the exciting relationships that are emerging between angiogenesis and the hemostatic and nervous systems... - Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathwayLiuliang Qin
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue RN 270A, Boston, MA 02215, USA
Mol Cancer Res 4:811-20. 2006..In sum, DSCR1-1L, unlike DSCR1-4, potently activates angiogenesis and could be an attractive target for antiangiogenesis therapy... - Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivoChristian Sundberg
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
Lab Invest 82:387-401. 2002.... - Vascular permeability and pathological angiogenesis in caveolin-1-null miceSung Hee Chang
Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
Am J Pathol 175:1768-76. 2009..Thus, caveolin-1 is not necessary for VVO structure but may have important roles in regulating VVO function in acute vascular hyperpermeability and angiogenesis... - Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycinThuy L Phung
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
Cancer Cell 10:159-70. 2006..Akt signaling in the tumor vascular stroma was sensitive to rapamycin, suggesting that rapamycin may affect tumor growth in part by acting as a vascular Akt inhibitor... - Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesisJanice A Nagy
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
J Exp Med 196:1497-506. 2002..These findings raise the possibility that similar, abnormal lymphatics develop in other pathologies in which VEGF-A is overexpressed, e.g., malignant tumors and chronic inflammation... - Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animalsDian Feng
Department of Pathology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts 02215, USA
Microsc Res Tech 57:289-326. 2002.... - VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formationSung Hee Chang
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
Cancer Res 69:4537-44. 2009.... - The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesisShou ching Shih
Center for Vascular Biological Research and Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Cancer Res 69:3272-7. 2009..Thus, TM4SF1 is a key regulator of EC function in vitro and of pathologic angiogenesis in vivo and is potentially an attractive target for antiangiogenesis therapy... - Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapyHarold F Dvorak
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Clin Oncol 20:4368-80. 2002..It may also become an important target for cancer therapy... - VEGF-A and the induction of pathological angiogenesisJanice A Nagy
Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Annu Rev Pathol 2:251-75. 2007..Elucidating the properties of these new vessels has led to a better understanding of angiogenesis and will hopefully lead to new approaches to antiangiogenic therapy... - Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatinRonit Satchi-Fainaro
Children s Hospital Boston and Harvard Medical School, Vascular Biology Program, Department of Surgery, 1 Blackfan Circle, Karp Family Research Laboratories, Floor 12, Boston, Massachusetts 02115, USA
Cancer Cell 7:251-61. 2005..This activity likely contributes to TNP-470's antiangiogenic effect and suggests that caplostatin can be used in the treatment of cancer and inflammation... - Ultrastructural localization of platelet endothelial cell adhesion molecule (PECAM-1, CD31) in vascular endotheliumDian Feng
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
J Histochem Cytochem 52:87-101. 2004..We conclude that CD31 is distributed over the entire endothelial cell surface, exclusive of specialized junctions, and in VVOs, but is not equally accessible to different antibodies in all locations... - Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activityHuiyan Zeng
Department of Pathology, Gastroenterology Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
J Exp Med 203:719-29. 2006..e., through transcriptional activity)... - Heterogeneity of the tumor vasculatureJanice A Nagy
Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Semin Thromb Hemost 36:321-31. 2010..A goal of future work is to identify therapeutic targets on tumor blood vessel endothelial cells that have lost this requirement... - VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesisJanice A Nagy
Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
Trends Cardiovasc Med 13:169-75. 2003.... - Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor levelXuefeng Zhang
Division of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
FASEB J 23:3368-76. 2009..Moreover, 3TSR significantly decreased VEGF-stimulated VEGFR2 phosphorylation in human dermal microvascular endothelial cells in culture. Taken together, the results indicate that TSP-1 and 3TSR modulate the function of VEGFR2... - Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6KinaseQi Xue
Center for Vascular Biology and the Department of Pathology at the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Arterioscler Thromb Vasc Biol 29:1172-8. 2009..We evaluated the stages of VEGF-A(164) driven angiogenesis that are inhibited by therapeutic doses of rapamycin and the potential role of S6K1 in that response... - Transcellular diapedesis is initiated by invasive podosomesChristopher V Carman
The CBR Institute for Biomedical Research, Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
Immunity 26:784-97. 2007..These findings provide insights into basic mechanisms for leukocyte trafficking and the functions of podosomes... - Permeability properties of tumor surrogate blood vessels induced by VEGF-AJanice A Nagy
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
Lab Invest 86:767-80. 2006..Extrapolating these findings to tumors predicts that only a subset of tumor vessels, MV and GMP, is hyperpermeable, and that measures of overall vessel permeability greatly underestimate the permeability of individual MV and GMP... 
Chapter 3. The adenoviral vector angiogenesis/lymphangiogenesis assayJanice A Nagy
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Methods Enzymol 444:43-64. 2008..The assay can be readily extended to the study of the new blood vessels/lymphatics induced by adenoviral vectors expressing other growth factors and cytokines...
Research Grants
- ADENOVIRAL VECTORS FOR DELIVERY OF ANGIOGENIC CYTOKINESHAROLD DVORAK; Fiscal Year: 2004..Define the origins, character and fate of glomeruloid bodies. 4.Compare the angiogenic response to ischemia with that induced by VPFNEGF164 and its 120 and 188 amino acid isoforms in ischemic and non-ischemic tissues. ..
- PERMSELECTIVE PROPERTIES OF TUMOR AND WOUND BLOOD VESSELHAROLD DVORAK; Fiscal Year: 2004..abstract_text> ..
- Spatial and Temporal Regulation of AngiogenesisHAROLD DVORAK; Fiscal Year: 2006..abstract_text> ..
- ADENOVIRAL VECTORS FOR DELIVERY OF ANGIOGENIC CYTOKINESHAROLD DVORAK; Fiscal Year: 2007..Aim 2. Elucidate the mechanisms by which mother vessels evolve into daughter vessels. Aim 3. Generate normal blood vessels with mixtures of primary and secondary cytokines. ..
- Training Program in Angiogenesis & InflammationHAROLD DVORAK; Fiscal Year: 2007..abstract_text> ..
- PERMSELECTIVE PROPERTIES OF TUMOR AND WOUND BLOOD VESSELHAROLD DVORAK; Fiscal Year: 1993..Comparison with monoclonal antibodies. 4. Mechanism(s) by which macromolecules extravasate from the leaky blood vessels of tumors and healing wounds...